





ARTICLE

Open Access

Dynamic functional connectivity and its anatomical substrate reveal treatment outcome in first-episode drug-naïve schizophrenia

Zhe Zhang ¹, Kaiming Zhuo², Qiang Xiang², Yi Sun³, John Suckling ⁴, Jinhong Wang⁵, Dengtang Liu ^{2,6,7} and Yu Sun ^{1,8}

Abstract

Convergent evidence has suggested a significant effect of antipsychotic exposure on brain structure and function in patients with schizophrenia, yet the characteristics of favorable treatment outcome remains largely unknown. In this work, we aimed to examine how large-scale brain networks are modulated by antipsychotic treatment, and whether the longitudinal changes could track the improvements of psychopathologic scores. Thirty-four patients with first-episode drug-naïve schizophrenia and 28 matched healthy controls were recruited at baseline from Shanghai Mental Health Center. After 8 weeks of antipsychotic treatment, 24 patients were re-scanned. Through a systematical dynamic functional connectivity (dFC) analysis, we investigated the schizophrenia-related intrinsic alterations of dFC at baseline, followed by a longitudinal study to examine the influence of antipsychotic treatment on these abnormalities by comparing patients at baseline and follow-up. A structural connectivity (SC) association analysis was further carried out to investigate longitudinal anatomical changes that underpin the alterations of dFC. We found a significant symptomatic improvement-related increase in the occurrence of a dFC state characterized by stronger inter-network integration. Furthermore, symptom reduction was correlated with increased FC variability in a unique connectomic signature, particularly in the connections within the default mode network and between the auditory, cognitive control, and cerebellar network to other networks. Additionally, we observed that the SC between the superior frontal gyrus and medial prefrontal cortex was decreased after treatment, suggesting a relaxation of normal constraints on dFC. Taken together, these findings provide new evidence to extend the dysconnectivity hypothesis in schizophrenia from static to dynamic brain network. Moreover, our identified neuroimaging markers tied to the neurobiology of schizophrenia could be used as potential indicators in predicting the treatment outcome of antipsychotics.

Introduction

Schizophrenia is a severe mental illness characterized by complex clinical symptoms, including hallucinations, delusions, and cognitive deficits¹. The heterogeneous

characteristics lead to significant challenges for efficacious treatment. In fact, more than 50% of patients received antipsychotic drugs fail to relief upon initial treatment^{2,3} despite some studies reported positive outcomes^{4,5}. Continuous efforts have been made to understand the neurobiological mechanisms of antipsychotic action that lead to favorable treatment outcome. The recent advent of neuroimaging techniques have highlighted the important role of brain connectivity in response to antipsychotic treatment that could serve as potential biomarkers for treatment assessment. For instance, previous longitudinal studies in schizophrenia have revealed that the resting-

Correspondence: Dengtang Liu (liudengtang@smhc.org.cn) or Yu Sun (yusun@zju.edu.cn)

¹Key Laboratory for Biomedical Engineering of Ministry of Education,

Department of Biomedical Engineering, Zhejiang University, Zhejiang, China

²First-episode Schizophrenia and Early Psychosis Program, Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Full list of author information is available at the end of the article

These authors have contributed equally: Zhe Zhang, Kaiming Zhuo

© The Author(s) 2021



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

state functional connectivity (FC) was increased after treatment and linked to symptoms improvement^{6–8}. Other similar studies have suggested that antipsychotic medications could significantly affect the FC, but altered connectivity was not associated with the relief of psychotic symptoms^{9–13}. The inconsistency of these findings may be partially due to an assumption that the functional couplings between brain regions are static, ignoring the time-varying properties of FC.

The human brain is known to be highly dynamic¹⁴. The recently-introduced dynamic FC (dFC) is considered to be an efficient way for uncovering specific functional integration properties that cannot be discovered through conventional static FC^{15–17}. Of note, schizophrenia is beginning to be revealed as abnormalities of dFC^{18–22}. Specifically, studies using graph theory-based approaches have revealed a disruption in dFC spatiotemporal efficiency^{23,24} and temporal variability^{25,26}, which could serve as potential biomarkers for schizophrenia classification²⁷. However, only one study, to the best of our knowledge, has attempted to examine the effects of antipsychotic exposure on dFC properties of schizophrenia and showed treatment effects of risperidone on dFC in insular in first-episode drug-naïve (FEDN) schizophrenia²⁸. It is still largely unknown how antipsychotic treatment might modify dynamic patterns in large-scale brain networks and whether these changes are related to symptomatic improvement longitudinally.

It is widely accepted that brain function is partially constrained by its anatomical substrates^{29,30}, with ample evidence of spatial correspondence between structural connectivity (SC) and FC^{31,32}. Thus, a comprehensive understanding of the effects of treatment on dFC should also consider SC as a scaffold for coordinated neural activity. For patients with schizophrenia, overlapping alterations of structure and function have been repeatedly reported^{33–36}. Additionally, the relationship of SC–FC within specific networks appears to be absent in patients with schizophrenia³⁷. Together, these findings suggest that disruptions of SC–FC coupling are implicated in the pathophysiology of schizophrenia. To date, no prior study has applied a combination analysis of SC and dFC to explore the effects of antipsychotic treatment on large-scale brain networks of schizophrenia.

The primary aim of this study is to investigate medication-induced dFC changes in large-scale brain networks in FEDN schizophrenia related to the relief of psychotic symptoms. A systematic analysis was performed to explore the dFC differences at baseline between patients and controls, followed by a longitudinal study to determine how altered dFC patterns change in response to antipsychotic treatment by comparing patients at baseline and follow-up. Furthermore, we performed an SC association analysis to examine the longitudinal changes

in anatomical constraints that support altered dFC in baseline patients, as well as longitudinal changes of its coupling with dFC. In particular, the SC with altered FC variability in baseline patients will be explored, so that we can focus the longitudinal changes of SC–dFC coupling on individual connection. Based upon the previous evidence supporting aberrant brain connectivity in schizophrenia, we hypothesized that: (1) the altered dFC in baseline patients is modified by treatment and tracks the improvement of psychopathologic scores; and (2) SC constrains altered dFC and their relationships at baseline in patients is modulated by antipsychotic treatment.

Materials and methods

Participants

Forty-six patients with FEDN schizophrenia and 32 matched healthy volunteers were recruited from the Shanghai Mental Health Center (SMHC) and local community. All the patients fulfilled the DSM-5 diagnostic criteria for schizophrenia, and all of them did not have any form of antipsychotic treatment prior to the initial scan. The detailed inclusion and exclusion criteria are described in Supplementary materials and Fig. S1. This study was approved by the Institutional Review Board of SHMC.

Medication and clinical assessments

The patients with FEDN schizophrenia were treated with second-generation antipsychotic (SGAs) for 8 weeks following the guidelines according to refs. ^{38,39}. Detailed information of medication and dosage for each patient is available in Table S1. The psychopathological symptoms of each patient were measured using the PANSS⁴⁰.

Image acquisition and preprocessing

All MRI data including T1-weighted, resting-state fMRI, and diffusion-weighted imaging (DWI) were acquired on a 3.0T Siemens Tim Verio scanner (Siemens, Germany) at SMHC. Patients were scanned both at baseline and 8 weeks follow-up, and healthy controls were scanned only at baseline. Participants were instructed to stay awake with their eyes closed, to remain still, and not to think systematically during the scan. Functional images were preprocessed using the DPARSF toolbox⁴¹, including removal of the 5 initial volumes, slice-timing, realignment, normalization, and spatial smoothing. Diffusion images were preprocessed using the PANDA toolbox⁴², which included estimating the brain mask, cropping the raw images, correcting for the eddy-current effect, and calculating diffusion metrics. Of note, to account for artifact of head motion, any data affected by head motion (maximal motion between volumes in each direction is greater than 1.5 mm, and rotation in each axis is greater than 1.5°) were discarded. We also calculated the mean frame-wise displacement (FD) of each participant on the

basis of realignment parameters and the participants with FD more than 0.2 mm were excluded. After head motion exclusion, 34 patients and 28 controls at baseline and 24 patients at follow-up were included in the subsequent analysis. Greater details of data preprocessing and criteria for significant head motion are provided in Supplementary methods. The analysis framework of this study is shown in Fig. S2.

Group independent component analysis

To identify the intrinsic connectivity networks (ICNs) and their corresponding time courses, we parcellated the fMRI data using a standard pipeline for spatial group independent component analysis (ICA)^{43,44}, including principal component analysis (PCA) to reduce subject-specific data, informax algorithm analysis to further reduce the concatenated subject-reduced data into independent components (ICs)⁴⁵, back reconstruction from group spatial maps to subject-specific spatial maps and estimate the corresponding time courses via group ICA approach. Of note, the global signal regression was performed as the standard PCA processing step prior to ICA implemented by GIFT toolbox. The ICA process resulted in 36 ICNs that were categorized into 7 resting-state networks (RSNs) including sub-cortical (SUC; 2 ICNs), auditory (AUD; 2 ICNs), visual (VIS; 5 ICNs), somato-motor (SM; 9 ICNs), cognitive control (CC; 9 ICNs), default mode (DM; 7 ICNs), and cerebellar (CB; 2 ICNs) networks. The activation information spatial maps of these ICNs are presented in Table S2 and Fig. S3. Additionally post-processing steps were performed on the time courses of the 36 ICNs to remove remaining noise sources, including detrending linear, quadratic and cubic signals, conducting regressions of the 6 realignment parameters and their temporal derivatives, despiking detected outliers, and low-pass filtering with a cutoff frequency of 0.15 Hz. See Supplementary materials for more details.

Dynamic functional connectivity estimation

A previously validated sliding window approach was used here to estimate dFC. Here, the time courses of ICNs were divided into a window with 22 TRs length and 1 TR increment-step, resulting in a total of 153 windows across the entire scan for each participant. Of note, we used the window length of 22 TRs since it has been demonstrated to provide a good cutoff between the quality of the correlation matrix estimation and the ability of to detect functional dynamics¹⁶. A 36×36 covariance matrix within each window was calculated to construct FC networks⁴⁶, wherein each ICN was defined as a node and the connectivity between two ICNs was defined as an edge. An L1 norm in the graphic LASSO framework with 100 repetitions⁴⁷ was further conducted to promote sparsity in

estimation. The obtained FC matrices were then converted to z-scores using Fisher's z-transformation and residualized with nuisance variables. The resulting 153 matrices for each participant represent the dynamic changes of FC networks over time. Since previous studies have suggested that dynamic connectivity patterns could be captured stably in the range of 30–60 s^{16,48}, we verified the findings by testing other window sizes (18–26 TRs).

Dynamic functional connectivity analysis

We then performed a systematical analysis to explore the treatment-related reorganization of dFC at multiple topological scales, ranging from the whole network to individual connectivity edges, with focus on the temporal properties of dFC states, dynamic network efficiency, and temporal variability of FC.

Temporal properties of dFC states

A k-means clustering analysis was initially performed on the dFC matrices of all participants to estimate reoccurring dFC states. The similarity between matrices and cluster centroids was measured using the L1 distance function⁴⁹. The optimal number of clusters = 5 was estimated by using the elbow criterion¹⁸. The obtained group centroids were used as the initial centroids to cluster each participant's windowed FC matrices. Of note, a state was considered as a reliable state when it covered at least 10 windows. Additionally, we conducted a k-means clustering analysis with other numbers of clusters ($k = 4, 6$) to verify the findings in this study. The temporal properties of dynamic states were then evaluated using a measure of state occurrence rate (the proportion of time spent in each state). A Mann–Whitney *U*-test was used to test the significance of a state occurrence between baseline patient and control groups, and a paired t-test was conducted between patients at baseline and follow-up. A FDR-corrected $P < 0.05$ was considered as significant.

Dynamic network efficiency

A network efficiency approach was then applied to examine the temporal variability of the topological organization of large-scale brain networks at both global and local level. Efficiency was calculated at a several sparsity thresholds from 0.1 to 0.35 according to ref. ⁴³. The area under the curve (AUC) within the defined threshold range for each measure of efficiency was estimated. The variance on the AUC changes across 153 windows was calculated to examine dynamic topology properties of the FC networks²⁴. The graph theory analyses were performed with GREYNET software (<http://www.nitrc.org/projects/gretna>). A Wilcoxon rank test was used to test the group difference in dynamic network efficiency ($P < 0.05$, FDR-corrected).

Temporal variability of FC

The temporal variability of FC was measured by calculating the FC variance in each pair of ICNs across all windows, which plays a key role in dynamically integrating and coordinating neural systems^{50,51}. Then the Network Based Statistics (NBS)⁵² was used to identify whether there was a group difference in connectome-based FC variability by comparing the baseline patient and control groups. Different from traditional statistical analysis, the NBS handles the multiple comparisons problem of the multiple edges in connectomic data by evaluating the null hypothesis at the level of interconnected sub-networks rather than individual connections⁵². NBS inference was by permutation testing using unpaired *t* tests with 5000 permutations. A test statistic was then computed for each connection, and a threshold of $t = 2.708$ was applied to identify a set of supra-threshold connections that showed significant differences in FC variability between baseline patient and control groups (significance at $P < 0.05$, FDR-corrected). To examine the longitudinal changes of FC variability after treatment, we used a paired *t*-test to test the group difference between patients at baseline and follow-up with permutation inference ($P < 0.05$, FDR-corrected).

SC–dFC association analysis

To observe how the anatomical constraints of altered dFC change in response to treatment, we used DWI to inform the SC between pairs of ICNs that showed altered FC variability in baseline patients. We transformed the ICNs in the MNI space to the native DWI space of each participant. First, the ICBM 152 template was registered to the b0 image of each participant in native DWI space using linear and nonlinear registration in FSL. Then, atlases from ICNs were transformed to each participant's native space with nearest-neighbor interpolation. White matter tracts were traced using a whole-brain deterministic tractography approach, which was performed in the native space for each participant using the fiber assessment by continuous tracking (FACT) algorithm. Here, fiber tracking was terminated when the angle between two consecutive orientations was $>45^\circ$ or when the FA value was <0.2 . In line with previous studies³⁶, the number of diffusion streamlines connecting pairs of regions was used as a measure of SC weights, which has been demonstrated as effective in detecting anatomical abnormalities both in first-episode and chronic schizophrenia patients^{53,54}. The strength of coupling between SC and dFC was examined by computing the level of Spearman's correlation between the weights of existing SC and its dFC counterparts. This correlation is referred to as the level of SC–dFC coupling ($P < 0.05$). Detailed information of SC estimation is provided in Supplementary methods.

Clinical and psychological data analysis

Group differences in demographics were explored using a two-sample *t*-test (age and education) and a chi-square test (gender). Differences in PANSS scores between patients at baseline and follow-up were examined using a paired *t*-test. Furthermore, we carried out Spearman's correlation analyses to investigate the relationships between alterations in brain measures (dFC and SC) and PANSS scores as well as between their longitudinal changes in schizophrenia patients, controlling for age, gender, mean frame-wise displacement, and daily dose of antipsychotic medication. Statistical analyses were performed using SPSS 24.0 (IBM Corporation, Armonk, NY, USA) and statistical significance was set at $P < 0.05$ with FDR-correction.

Results

Demographic and clinical characteristics

Healthy controls and patients at baseline did not differ in age, gender, and education (all tests $P > 0.05$). The mean duration since onset of psychiatric symptoms for baseline patients was 6.7 months (SD = 11.9). After 8 weeks of antipsychotic treatment, we found a significant reduction on PANSS total score, positive symptoms, negative symptoms, and general symptoms ($P < 0.0001$). Detailed demographic and clinical characteristics of the included participants are shown in Table 1.

Occurrences of dFC patterns

The cluster centroid of 5 dFC states across participants is shown in Fig. 1. Supplementary Fig. S4 shows group-specific cluster centroids for each state. Compared with controls, baseline patients showed a lower occurrence rate in State 5 ($P = 0.0098$, FDR-corrected), which exhibited strongly positive couplings between AUD and VIS, and SM networks as well as between VIS and SM networks, representing a high sensory-network interaction state. We then investigated the longitudinal changes of state occurrence in response to antipsychotic treatment and observed that the occurrence rate in State 3 was significantly increased in patients after treatment compared with that at baseline ($P = 0.0058$). State 3 exhibited strongly positive couplings among SUC, AUD, SM, and CC, as well as negative DM couplings with SUC, AUD, SM, and CC, representing a strong inter-network integration state. Spearman's correlation analysis further showed that the increased occurrence rate in State 3 was significantly related with decreased PANSS score after treatment. Moreover, we found that these findings were independent of different settings of sliding window (Figs. S5, S6) and clusters (Figs. S7, S8), and global signal (Fig. S9), indicating a medication-induced intrinsic reorganization of dFC that were associated with relief of psychotic symptoms after treatment.

Table 1 Demographics and clinical characteristics from study groups.

	SZ_b (n = 34)	SZ_p (n = 24)	HC (n = 28)	SZ_b versus HC (P-value)	SZ_bp versus SZ_p (P-value)
Age (y)	27.1 ± 6.1	27.4 ± 5.7	27.1 ± 4.5	0.99 ^c	\
Gender (f)	17	12	15	0.78 ^d	\
Handedness (l/r)	0/34	0/24	0/28	\	\
Education (y)	12.9 ± 3.2	13.2 ± 3.2	14.4 ± 2.2	0.06 ^c	\
^a DUP (m)	6.7 ± 11.9	\	\	\	\
^b Antipsychotic dose(in CPZE, mg)	\	339.6 ± 137.5	\	\	\
PANSS total score	74.0 ± 17.8	48.3 ± 14.0	\	\	<0.0001 ^e
positive symptoms	20.3 ± 5.3	11.0 ± 3.6	\	\	<0.0001 ^e
negative symptoms	16.6 ± 6.1	12.3 ± 4.8	\	\	<0.0001 ^e
general symptoms	37.1 ± 9.4	25.0 6.7	\	\	<0.0001 ^e

Values are mean ± SD or N.

y year, f female, m month, l left, r right, DUP duration of untreated psychosis.

^aDUP of each FEDN schizophrenia patient was determined by psychiatrists from the disease onset until the first clinical examination.

^bThe daily antipsychotic dose converted to chlorpromazine equivalents (CPZE).

^cStatistical differences were obtained using two-sample t-test.

^dStatistical differences were obtained using Chi-square test.

^eStatistical differences were obtained using paired t-test.

Temporal variability of dFC

We investigated the dynamic network efficiency in time-varying functional brain networks and found insignificant difference between both groups at baseline (Fig. S10). We then explored the schizophrenia-related alterations of FC variability and revealed a pre-treatment connectomic signature that showed a significant difference in FC variance between both groups at baseline (SZ_b < HC; $P = 0.016$, FEW-corrected). This signature was characterized by lower FC variability within DM and CC as well as between multiple other RSNs (i.e., DM and AUD, SM, CC, CB; CC and AUD, CB; SM and VIS, CB) (Fig. 2). Moreover, we observed that the FC variability of this signature was increased in patients after treatment compared with that at baseline, although the group difference showed a marginally statistical significance ($P = 0.058$).


We further evaluated the association between FC variability and clinical measures in patients. There was no significant correlation at baseline ($r = -0.11$, $P = 0.5234$), but a significantly negative correlation at follow-up ($r = -0.41$, $P = 0.0439$). Importantly, we observed that increased FC variability was significantly correlated with decreased PANSS total score after treatment ($r = 0.53$, $P = 0.0080$). Further analysis indicated that the significant correlations ($P < 0.05$) involved the intro-network connections of DM, as well as the inter-network connections between AUD, CC, and CB to other RSNs (Fig. 3). These analyses suggest that relief of psychotic symptoms in patients after treatment is associated with increased FC variability within and between specific brain networks.

Association between dFC and SC

To investigate the longitudinal changes in SC that support altered dFC in baseline patients, we tracked the number of DWI streamlines connecting pairs of ICNs identified as connectomic signatures as having lower FC variability. We found that the number of reconstructed streamlines between IC94 (SFG) and IC97 (MPFC) was significantly decreased in patients after treatment compared with that baseline ($P = 0.0023$) (Fig. 4). Additionally, decreased fiber numbers were negatively correlated with decreased PANSS scores after treatment ($r = -0.39$, $P = 0.0579$). We further observed the relationships in the SFG-MPFC connection between FC variability and number of fiber streamlines for each group. A significant association between FC variability and number of fiber streamlines was found at baseline in patients ($r = -0.37$, $P = 0.0324$), while this relationship was not present in controls ($r = -0.16$, $P = 0.4101$) or treated patients ($r = -0.31$, $P = 0.1285$), suggesting a decoupling of SC and dFC for schizophrenia patients in response to antipsychotic treatment.

Discussion

In this study, we performed a systematical dFC analysis to investigate how antipsychotic medication modifies large-scale brain networks in FEDN schizophrenia and how these alterations relate to changes in symptoms. The present results establish a significant relationship between brain networks and clinical relief. Specifically, the longitudinal changes of dFC state occurrence and FC variability emerged as key indicators of symptomatic improvement in schizophrenia. Moreover, SC association analyses indicate




that the anatomical constraints to support dFC and their association were modified longitudinally by antipsychotic treatment. Thus, the present work provides the novel evidence for neurobiological mechanisms of antipsychotic treatment that lead to symptomatic improvement, and underscore the potential of dynamic functional brain networks in searching prognostic markers and predicting treatment response of schizophrenia.

Occurrence of dFC patterns changes longitudinally and tracks symptomatic improvement

Our results demonstrated significant group differences in the occurrence of dFC states. That the baseline patients spent much less time than controls in State 5 is consistent with prior findings in chronic schizophrenia^{18,20,22}. State 5 was characterized by strong interactions between sensory networks, and it represents a state of low alertness or drowsiness in the human brain¹⁶. The lower occurrence of this state may reflect an

excessive level of arousal or an inability to be in relaxation that may lead to diverse symptoms of schizophrenia²². It can be supported by the relationships established in our study, where the lower occurrence in State 5 was linked to more severe clinical symptoms (Fig. S11). More importantly, we found that the occurrence of State 3 in patients after treatment was higher than baseline. This finding is partly consistent with a previous work that the dwell time of dFC states was changed in patients with chronic schizophrenia after 6 weeks of risperidone treatment¹¹. Specifically, state 3 was characterized by stronger positive couplings among multiple networks (i.e. SC, AUD, SM and CC), as well as negative correlations between DM and these networks. The increased occurrence of this state may reflect a reinforced global integration of the brain networks in patients after treatment and thus contribute to the improvement of psychosis symptoms. Our results could also be interpreted as a potential compensatory mechanism of dFC




states in response to antipsychotic treatment, where antipsychotic drugs did not normalize the occurrence of a strong sensory-network interaction state, but instead enhanced the expression of a strong inter-network integration state. Future studies are required to clarify the relevance of these dFC states, particularly State 3, with brain cognitive states, as well as their neurophysiological mechanism in response to antipsychotic treatment.

FC variability changes longitudinally and tracks symptomatic improvement

Our findings of a baseline deficit in dFC variability in patients are consistent with a report of reduced FC dynamism in clinical high-risk individuals for schizophrenia⁵⁵. It has been suggested that a higher FC variability may reflect a greater complexity and greater capacity for information processing^{26,56,57}. Thus, the lower FC variability we observed may indicate decreased ability for information processing in patients. Moreover, we found that FC variability of this connectomic signature was increased in patients with greater symptomatic reduction after treatment, suggesting a medication-induced normalization. Indeed, the findings of time-invariant FC studies have reported that successful treatment is often linked to the normalization of regional FC^{9,13}. It is therefore intriguing to assume that the increases in FC variability caused by


antipsychotic medications may modulate the corresponding spatiotemporal changes on the psychological level which, in turn, improve psychosis symptoms, corresponding to what has been described as “Spatiotemporal Psychopathology”^{58,59}. Further results demonstrated that the symptomatic improvement-related FC variability in this signature was mainly involved with intra-network connections of DM and inter-network connections of AUD, CC, and CB, which are well known to be implicated in schizophrenia. Specifically, dysfunction in the DM may lead to the disturbances of self-referential processing in patients⁶⁰. Convergent evidence has linked symptomatic improvement to FC changes within the DM^{9,13,61}. Consistently, our increased FC variability within the DM suggest that self-related thought plays a pivotal role in recovery from psychosis symptoms. Additionally, dysconnectivity of the primary sensory networks (e.g., AUD and CB) with other high-order cognitive networks (e.g., CC) is considered to be related to symptoms such as hallucinations and emotional dysregulation^{62–65}, and abnormal CC connectivity to other networks might lead to various executive control deficits in patients with schizophrenia^{66,67}. Overall, our findings, therefore, provide solid evidence supporting that symptomatic reduction in response to antipsychotic treatment is associated with normalization of FC variability in multiple large-scale networks implicated in the pathophysiology of schizophrenia.



SC-dFC coupling changes longitudinally

A particularly important objective of our study was to explore whether the structure underpinnings of altered

FC variability in baseline patients and their relationship can be modulated by antipsychotic treatment. It has been suggested that antipsychotic medications have an effect



on myelin content, thus changing whiter matter (WM) microstructure. Studies using DTI have frequently revealed WM tract changes in relation to 6–12 weeks of antipsychotic exposure, ranging from white matter integrity to network topologic organization^{54,68–70}. Our results add to previous findings, suggesting that the SC between the SFG and MPFC can be modulated by pharmacological intervention, especially during the early phase of treatment. However, it is not possible to entirely exclude the influences of underlying progression of illness. We also observed that symptom reduction was anti-correlated with decreased SC between the SFG and MPFC, suggesting that antipsychotic drugs might attenuate clinical features of schizophrenia by delaying the reduction of WM tracts. Our results can be supported by previous findings that antipsychotic-treated patients exhibited much less reduction of fractional anisotropy than never-treated patients in brain structure⁷¹. Moreover, we observed that the FC variability between the SFG and MPFC was negatively correlated with its SC counterparts in baseline patients, but this relationship was lost after treatment, suggesting that antipsychotic treatment may induce a decoupling of SC–dFC on this connection. Contemporary theories have suggested that aberrant relationships of SC and (static) FC could lead to deficits in executive function as well as the emergence of neuropsychiatric disorders such as schizophrenia^{36,72–74}. In this study, we extend these findings by showing a tightly coupled SC and dFC at baseline in patients, which reflects

a less dynamic or more stringent functional communication between the SFG and MPFC, may be directly constrained by its underlying white matter structure. Echoing the triple-network hypothesis of schizophrenia^{75,76}, the decoupling after treatment suggests an increased functional flexibility and dynamic recruitment to balance internally generated thoughts and externally stimulated executive processing^{77,78}, and thus contribute to the relief of psychotic symptoms in schizophrenia patients.

Clinical implications

Our findings may contribute to the future therapy for schizophrenia in the following two aspects. First, our study sheds light on the neural pathophysiology underlying therapeutic effects of antipsychotic treatment. Although attempts have been made to determine neuroimaging-based biomarkers that relate to treatment response, the findings are inconsistent^{6–12}. Our study, from the perspective of large-scale brain networks, provides a new avenue for exploring potential markers of treatment that contribute to symptom reduction. Second, our study provides important information in the search for clinically useful prognostic markers of schizophrenia. Recently, many researchers have examined whether brain connectivity can be used to predict response to antipsychotic treatment^{54,79–82}. In our study, we used baseline dFC features to predict symptomatic improvement after treatment. Our results indicate that the dFC features can

significantly improve prediction performance compared to models using demographic and clinical measures alone. Specifically, we obtained the cross-validated accuracy of a model without dynamic features/with dynamic features = 0.40/0.55, $P = 0.0552/0.0052$ (Fig. S12). Given the limited sample sizes in our study, however, this high prediction performance should be verified in further longitudinal research.

Limitations

Our study was subject to a few limitations that deserve mention. First, to investigate the changes caused by direct antipsychotic treatment rather than a potential effect of the disease itself, we opted for a modest homogeneous cohort of FEDN schizophrenia instead of a large heterogeneous cohort. Our patients are older than the patients included in previous studies^{82,83}. Future study with a larger and younger homogeneous cohort is needed to validate our findings. Second, all patients were treated with the SGA medication. However, previous findings have suggested that different antipsychotic agents vary in their potency and effects on brain structure and function³. It would be important for a further study to determine whether the changes observed here were general or specific across different types of antipsychotics. Third, although our study has focused on the structural underpinnings of a connectomic signature with lower FC variability, it has been suggested that medication-induced SC changes can be preserved between brain regions that show normal functional coupling. That means the alterations of SC–dFC coupling after treatment can be found even on the connections outside the connectomic signature. Therefore, future studies in schizophrenia should measure the treatment-induced changes in whole-brain SC–dFC coupling.

In conclusion, our study investigated the modification of large-scale brain networks caused by antipsychotic medications in FEDN schizophrenia. We have shown, for the first time, that longitudinal changes of occurrence of dFC states and FC variability can track symptomatic improvement in response to antipsychotic treatment. Furthermore, the SC constraints of altered dFC, as well as their relationships, are longitudinally altered by medications. Overall, these findings demonstrate that antipsychotic treatment can ease psychotic symptoms by modulating large-scale brain networks, which opens up new avenues to develop a target for novel therapeutic interventions and to identify an indicator of long-term prognosis.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81801785 and 81871047), by Key Program of Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University (No. YG2017ZD13), by Key Program of Shanghai Mental Health Center Clinical Research Center (No.

CRC2017ZD03), by Shanghai Key Laboratory of Psychotic Disorders (No. 13dz22260500), by the “Hundred Talents Program” of Zhejiang University, by the Fundamental Research Funds for the Central Universities (No. 2019FZJD005 and 2020FZZX001-05), by the Zhejiang Lab (No. 2019KE0AD01), by the China Postdoctoral Science Foundation (No. 2020M681865), and by Gansu Province Universities and Colleges Scientific Research Project (No. 2018A-124).

Author details

¹Key Laboratory for Biomedical Engineering of Ministry of Education, Department of Biomedical Engineering, Zhejiang University, Zhejiang, China. ²First-episode Schizophrenia and Early Psychosis Program, Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ³Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, China. ⁴Brain Mapping Unit, Department of Psychiatry, School of Clinical Medicine, Herchel Smith Building for Brain and Mind Sciences, University of Cambridge, Cambridge, UK. ⁵Department of Medical Imaging, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁶Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁷Institute of Mental Health, Fudan University, Shanghai, China. ⁸Zhejiang Lab, Zhejiang, China

Data availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Conflict of interest

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41398-021-01398-4>.

Received: 13 January 2021 Revised: 9 April 2021 Accepted: 20 April 2021
Published online: 12 May 2021

References

- McCutcheon, R. A., Reis Marques, T. & Howes, O. D. Schizophrenia—an overview. *JAMA Psychiatry* **77**, 201–210 (2019).
- Boter, H. et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). *Schizophr. Res* **115**, 97–103 (2009).
- Taricjonas, G. & Sarpal, D. K. Neuroimaging markers of antipsychotic treatment response in schizophrenia: an overview of magnetic resonance imaging studies. *Neurobiol. Dis.* **131**, 104209 (2019).
- Kane, J. M. & Correll, C. U. Past and present progress in the pharmacologic treatment of schizophrenia. *J. Clin. Psychiatry* **71**, 1115–1124 (2010).
- Remington, G. et al. Treating negative symptoms in schizophrenia: an update. *Curr. Treat. Options Psychiatry* **3**, 133–150 (2016).
- Anticevic, A. et al. Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change. *J. Neurosci.* **35**, 267–286 (2015).
- Kraguljac, N. V. et al. Aberrant hippocampal connectivity in unmedicated patients with schizophrenia and effects of antipsychotic medication: a longitudinal resting state functional MRI study. *Schizophr. Bull.* **42**, 1046–1055 (2016).
- Sarpal, D. K. et al. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. *JAMA Psychiatry* **72**, 5–13 (2015).
- Guo, W. et al. Treatment effects of olanzapine on homotopic connectivity in drug-free schizophrenia at rest. *World J. Biol. Psychiatry* **19**, S106–S114 (2018).
- Kraguljac, N. V. et al. Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. *NeuroImage Clin.* **10**, 146–158 (2016).

11. Lottman, K. K. et al. Risperidone effects on brain dynamic connectivity—a prospective resting-state fMRI study in schizophrenia. *Front. psychiatry* **8**, 14 (2017).
12. Lui, S. et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naïve first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. *Arch. Gen. Psychiatry* **67**, 783–792 (2010).
13. Wang, Y. et al. Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia. *Neuropsychiatr. Dis. Treat.* **13**, 397–406 (2017).
14. Calhoun, V. D., Miller, R., Pearlson, G. & Adali, T. The chronnectome: time-varying connectivity networks as the next frontier in fMRI data discovery. *Neuron* **84**, 262–274 (2014).
15. Calhoun, V. D. & Adali, T. Time-varying brain connectivity in fMRI data: whole-brain data-driven approaches for capturing and characterizing dynamic states. *IEEE Signal Process. Mag.* **33**, 52–66 (2016).
16. Allen, E. A. et al. Tracking whole-brain connectivity dynamics in the resting state. *Cereb. Cortex* **24**, 663–676 (2014).
17. Lurie, D. J. et al. Questions and controversies in the study of time-varying functional connectivity in resting fMRI. *Netw. Neurosci.* **4**, 30–69 (2020).
18. Damaraju, E. et al. Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia. *NeuroImage Clin.* **5**, 298–308 (2014).
19. Miller, R. L. et al. Higher dimensional meta-state analysis reveals reduced resting fMRI connectivity dynamism in schizophrenia patients. *PLoS ONE* **11**, e0149849 (2016).
20. Rabany, L. et al. Dynamic functional connectivity in schizophrenia and autism spectrum disorder: convergence, divergence and classification. *NeuroImage Clin.* **24**, 101966 (2019).
21. Salman, M. S., Vergara, V. M., Damaraju, E. & Calhoun, V. D. Decreased cross-domain mutual information in schizophrenia from dynamic connectivity states. *Front. Neurosci.* **13**, 873 (2019).
22. Weber, S. et al. Dynamic functional connectivity patterns in schizophrenia and the relationship with hallucinations. *Front. Psychiatry* **11**, 227 (2020).
23. Sun, Y., Collinson, S. L., Suckling, J. & Sim, K. Dynamic reorganization of functional connectivity reveals abnormal temporal efficiency in schizophrenia. *Schizophr. Bull.* **45**, 659–669 (2019).
24. Yu, Q. et al. Assessing dynamic brain graphs of time-varying connectivity in fMRI data: application to healthy controls and patients with schizophrenia. *NeuroImage* **107**, 345–355 (2015).
25. Dong, D. et al. Reconfiguration of dynamic functional connectivity in sensory and perceptual system in schizophrenia. *Cereb. Cortex* **29**, 3577–3589 (2019).
26. Guo, S., Zhao, W., Tao, H., Liu, Z. & Palaniyappan, L. The instability of functional connectivity in patients with schizophrenia and their siblings: a dynamic connectivity study. *Schizophr. Res.* **195**, 183–189 (2018).
27. Kottaram, A. et al. Spatio-temporal dynamics of resting-state brain networks improve single-subject prediction of schizophrenia diagnosis. *Hum. Brain Mapp.* **39**, 3663–3681 (2018).
28. Duan, X. et al. Effect of risperidone monotherapy on dynamic functional connectivity of insular subdivisions in treatment-naïve, first-episode schizophrenia. *Schizophr. Bull.* **46**, 650–660 (2020).
29. Deco, G. et al. Resting-state functional connectivity emerges from structurally and dynamically shaped slow linear fluctuations. *J. Neurosci.* **33**, 11239–11252 (2013).
30. Honey, C. J. et al. Predicting human resting-state functional connectivity from structural connectivity. *Proc. Natl Acad. Sci. USA* **106**, 2035–2040 (2009).
31. Goni, J. et al. Resting-brain functional connectivity predicted by analytic measures of network communication. *Proc. Natl Acad. Sci. USA* **111**, 833–838 (2014).
32. Misić, B. et al. Network-level structure-function relationships in human neocortex. *Cereb. cortex* **26**, 3285–3296 (2016).
33. Camchong, J., MacDonald, A. W. 3rd, Bell, C., Mueller, B. A. & Lim, K. O. Altered functional and anatomical connectivity in schizophrenia. *Schizophr. Bull.* **37**, 640–650 (2011).
34. Yan, H. et al. Functional and anatomical connectivity abnormalities in cognitive division of anterior cingulate cortex in schizophrenia. *PLoS ONE* **7**, e45659 (2012).
35. Sun, Y., Dai, Z., Li, J., Collinson, S. L. & Sim, K. Modular-level alterations of structure-function coupling in schizophrenia connectome. *Hum. Brain Mapp.* **38**, 2008–2025 (2017).
36. van den Heuvel, M. P. et al. Abnormal rich club organization and functional brain dynamics in schizophrenia. *JAMA psychiatry* **70**, 783–792 (2013).
37. Cocchi, L. et al. Disruption of structure-function coupling in the schizophrenia connectome. *NeuroImage Clin.* **4**, 779–787 (2014).
38. Taylor, D. M., Thomas, R. E. B. & Allan, H. Y. *The Maudsley Prescribing Guidelines in Psychiatry* (John Wiley & Sons, 2018).
39. Kuipers, E. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). (ed. Taylor C. Leicester), (British Psychological Society, UK, 2009)
40. Kay, S. R., Fiszbein, A. & Opfer, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bull.* **13**, 261–276 (1987).
41. Yan, C. & Zang, Y. DPARSF: A MATLAB Toolbox for "Pipeline" data analysis of resting-state fMRI. *Front. Syst. Neurosci.* **4**, 13 (2010).
42. Cui, Z., Zhong, S., Xu, P., He, Y. & Gong, G. PANDA: a pipeline toolbox for analyzing brain diffusion images. *Front. Hum. Neurosci.* **7**, 42 (2013).
43. Tu, Y. et al. Abnormal thalamocortical network dynamics in migraine. *Neurology* **92**, e2706–e2716 (2019).
44. Kim, J. et al. Abnormal intrinsic brain functional network dynamics in Parkinson's disease. *Brain* **140**, 2955–2967 (2017).
45. Bell, A. J. & Sejnowski, T. J. An information-maximization approach to blind separation and blind deconvolution. *Neural Comput.* **7**, 1129–1159 (1995).
46. Smith, S. M. et al. Network modelling methods for fMRI. *NeuroImage* **54**, 875–891 (2011).
47. Friedman, J., Hastie, T. & Tibshirani, R. Sparse inverse covariance estimation with the graphical lasso. *Biostatistics* **9**, 432–441 (2008).
48. Hutchison, R. M. et al. Dynamic functional connectivity: promise, issues, and interpretations. *NeuroImage* **80**, 360–378 (2013).
49. Aggarwal, C. C., Hinneburg, A. & Keim, D. A. *On the Surprising Behavior of Distance Metrics in High Dimensional Space* (Springer, New York, NY, 2001).
50. Qin, Y. et al. BOLD-fMRI activity informed by network variation of scalp EEG in juvenile myoclonic epilepsy. *NeuroImage Clin.* **22**, 101759 (2019).
51. Hutchison, R. M., Womelsdorf, T., Gati, J. S., Everling, S. & Menon, R. S. Resting-state networks show dynamic functional connectivity in awake humans and anesthetized macaques. *Hum. Brain Mapp.* **34**, 2154–2177 (2013).
52. Zalesky, A., Fornito, A. & Bullmore, E. T. Network-based statistic: identifying differences in brain networks. *NeuroImage* **53**, 1197–1207 (2010).
53. van den Heuvel, M. P., Scholtens, L. H., de Reus, M. A. & Kahn, R. S. Associated microscale spine density and macroscale connectivity disruptions in schizophrenia. *Biol. Psychiatry* **80**, 293–301 (2016).
54. Crossley, N. A. et al. Connectomic correlates of response to treatment in first-episode psychosis. *Brain* **140**, 487–496 (2017).
55. Mennigen, E. et al. Reduced higher-dimensional resting state fMRI dynamism in clinical high-risk individuals for schizophrenia identified by meta-state analysis. *Schizophr. Res.* **201**, 217–223 (2018).
56. Marusak, H. A. et al. Dynamic functional connectivity of neurocognitive networks in children. *Hum. Brain Mapp.* **38**, 97–108 (2016).
57. Wang, J. et al. Abnormal intrinsic brain functional network dynamics in unmedicated depressed bipolar II disorder. *J. Affect. Disord.* **253**, 402–409 (2019).
58. Northoff, G. & Duncan, N. W. How do abnormalities in the brain's spontaneous activity translate into symptoms in schizophrenia? From an overview of resting state activity findings to a proposed spatiotemporal psychopathology. *Prog. Neurobiol.* **145–146**, 26–45 (2016).
59. Northoff, G. et al. Too fast or too slow? Time and neuronal variability in bipolar disorder—a combined theoretical and empirical investigation. *Schizophr. Bull.* **44**, 54–64 (2018).
60. Whitfield-Gabrieli, S. & Ford, J. M. Default mode network activity and connectivity in psychopathology. *Annu Rev. Clin. Psychol.* **8**, 49–76 (2012).
61. Sambataro, F. et al. Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia. *Neuropsychopharmacology* **35**, 904–912 (2010).
62. Curcio-Blake, B. et al. Interaction of language, auditory and memory brain networks in auditory verbal hallucinations. *Prog. Neurobiol.* **148**, 1–20 (2017).
63. He, H. et al. Reduction in gray matter of cerebellum in schizophrenia and its influence on static and dynamic connectivity. *Hum. Brain Mapp.* **40**, 517–528 (2019).
64. Kim, N. Y. et al. Lesions causing hallucinations localize to one common brain network. *Mol. Psychiatry* **26**, 1299–1309 (2021).
65. Valton, V. et al. Acquisition of visual priors and induced hallucinations in chronic schizophrenia. *Brain* **142**, 2523–2537 (2019).
66. Berman, R. A. et al. Disrupted sensorimotor and social-cognitive networks underlie symptoms in childhood-onset schizophrenia. *Brain* **139**, 276–291 (2016).

67. McNabb, C. B. et al. Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia. *Schizophr. Res.* **195**, 160–167 (2018).
68. Luck, D. et al. Fronto-temporal disconnectivity and clinical short-term outcome in first episode psychosis: a DTI-tractography study. *J. Psychiatr. Res.* **45**, 369–377 (2011).
69. Serpa, M. H. et al. State-dependent microstructural white matter changes in drug-naive patients with first-episode psychosis. *Psychological Med.* **47**, 2613–2627 (2017).
70. Zeng, B. et al. Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment. *Schizophr. Res.* **172**, 1–8 (2016).
71. Xiao, Y. et al. White matter abnormalities in never-treated patients with long-term schizophrenia. *Am. J. Psychiatry* **175**, 1129–1136 (2018).
72. Baum, G. L. et al. Modular segregation of structural brain networks supports the development of executive function in youth. *Curr. Biol.* **27**, 1561–1572 (2017).
73. Di Martino, A. et al. Unraveling the miswired connectome: a developmental perspective. *Neuron* **83**, 1335–1353 (2014).
74. Stephan, K. E., Baldeweg, T. & Friston, K. J. Synaptic plasticity and dysconnection in schizophrenia. *Biol. Psychiatry* **59**, 929–939 (2006).
75. Menon, V. Large-scale brain networks and psychopathology: a unifying triple network model. *Trends Cogn. Sci.* **15**, 483–506 (2011).
76. Palaniyappan, L., Mallikarjun, P., Joseph, V., White, T. P. & Liddle, P. F. Regional contraction of brain surface area involves three large-scale networks in schizophrenia. *Schizophr. Res.* **129**, 163–168 (2011).
77. Yeo, B. T. et al. Functional specialization and flexibility in human association cortex. *Cereb. Cortex* **25**, 3654–3672 (2015).
78. Baum, G. L. et al. Development of structure-function coupling in human brain networks during youth. *Proc. Natl Acad. Sci. USA* **117**, 771–778 (2020).
79. Cao, B. et al. Treatment response prediction and individualized identification of first-episode drug-naive schizophrenia using brain functional connectivity. *Mol. Psychiatry* **25**, 906–913 (2020).
80. Doucet, G. E., Moser, D. A., Luber, M. J., Leibu, E. & Frangou, S. Baseline brain structural and functional predictors of clinical outcome in the early course of schizophrenia. *Mol. Psychiatry* **25**, 863–872 (2020).
81. Sarpal, D. K. et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. *Am. J. Psychiatry* **173**, 69–77 (2016).
82. Tarcijonas, G., Foran, W., Haas, G. L., Luna, B. & Sarpal, D. K. Intrinsic connectivity of the globus pallidus: an uncharted marker of functional prognosis in people with first-episode schizophrenia. *Schizophr. Bull.* **46**, 184–192 (2020).
83. Kraguljac, N. V. et al. White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naive first-episode psychosis patients. *Mol. Psychiatry*, <https://doi.org/10.1038/s41380-020-0765-x> (2020).